HER2 is a promising multi-tumor target beyond breast cancer. Various therapies, including ADCs, multispecific antibodies, cell therapy, and radiopharmaceuticals, are showing great results. This event covers all challenges in HER2 treatment, from preclinical to post-approval indication-agnostic trials.
Timings09:00 AM-06:00 PM (expected)
Entry FeesCheck Official Website
Estimated Turnout100 - 500
DelegatesBased on previous editions
Frequency Not Available
Claim this event
Queries about the event? Ask Organizer
467 Total Events • 139 Followers
How did you participate in this event?
Followers [ Users who have shown interest for this Event ] Join Community Invite